DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Norman-Roberts syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNorman-Roberts syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for norman-roberts syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
No drug treatment is described in any of these abstracts. All four papers are case reports or reviews that focus on the genetic cause and clinical features of Roberts syndrome. The condition is caused by autosomal recessive loss-of-function mutations in the ESCO2 acetyltransferase gene on chromosome 8p21. ESCO2 is required for the cohesin complex to carry out sister chromatid cohesion, chromosome condensation, transcription, and DNA repair. The molecular mechanism that leads to the physical abnormalities remains ambiguous, though one review suggests a possible role for macromolecular damage.
The clinical features reported across these papers include craniofacial abnormalities, tetraphocomelia (malformed or missing limbs), growth and mental retardation, bilateral cleft lip and palate, bilateral corneal opacity, cardiac and renal abnormalities, and early mortality or stillbirth. One case describes a five-year-old female with bilateral cleft lip and palate, which the authors call extremely rare. Another reports two siblings with bilateral corneal opacity. No sample sizes larger than individual case reports are given.
No trial, no drug, no intervention of any kind is mentioned in any of these abstracts. What is missing is any preclinical or clinical testing of a pharmacological agent, any patient stratification strategy, and any funding directed toward drug development for Roberts syndrome.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PLoS Genetics · 2020 · 19 citations · open access
An ever-changing landscape in Roberts syndrome biology: Implications for macromolecular damage
AbstractRoberts syndrome (RBS) is a rare developmental disorder that can include craniofacial abnormalities, limb malformations, missing digits, intellectual disabilities, stillbirth, and early mortality. The genetic basis for RBS is linked to autosomal recessive loss-of-function mutation of the establishment of cohesion (ESCO) 2 acetyltransferase. ESCO2 is an essential gene that targets the DNA-binding cohesin complex. ESCO2 acetylates alternate subunits of cohesin to orchestrate vital cellular processes that include sister chromatid cohesion, chromosome condensation, transcription, and DNA repair. Although significant advances were made over the last 20 years in our understanding of ESCO2 and cohesin biology, the molecular etiology of RBS remains ambiguous. In this review, we highlight current models of RBS and reflect on data that suggests a novel role for macromolecular damage in the molecular etiology of RBS.
Journal of Craniofacial Surgery · 2020 · 2 citations
Roberts Syndrome With a Bilateral Cleft Lip and Palate
AbstractABSTRACT: Roberts syndrome (RBS) is a rare craniofacial anomaly associated with tetraphocomelia, growth and mental retardation, cardiac and renal abnormalities. The RBS is caused by homozygous mutation in the ESCO2 gene on chromosome 8p21. In this report, the authors describe a 5-year-old female infant with RBS and bilateral cleft lip and cleft palate, an extremely rare condition.
Indian Journal of Ophthalmology - Case Reports · 2022 · 0 citations · open access
Roberts syndrome with bilateral corneal opacity
AbstractRoberts syndrome (RBS) is a rare autosomal recessive genetic disorder. Mutation in the ESCO2 (establishment of cohesion 1 homologue 2) gene has been reported to cause disease. Patients with RBS may have many ophthalmologic pathologies such as hypertelorism, down slating palpebral fissures, corneal opacity, and congenital cataract. Here, we report the case of two siblings who were diagnosed with RBS and were followed in our clinic.
Chinese journal of plastic surgery · 2018 · 0 citations
Roberts syndrome
AbstractRoberts syndrome (RBS, OMIM 268300) is a rare autosomal recessive disease, characterized by retardation before and after birth, cranial and maxillofacial deformities, limb anomalies and mental retardation, etc. Mutations in the establishment of cohesion 1 homolog 2(ESCO2) gene on the chromosome of 8p21.1 have been found to be causative for RBS.Here we systematically review this rare disease and summarize the pathogenic mechanisms and process in its treatment.
Key words:
Roberts syndrome; Pathogenesis
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
